A retrospective global study of the prevalence of O-serotypes of invasive Escherichia coli disease in patients admitted to tertiary care hospitals.
Saved in:
| Title: | A retrospective global study of the prevalence of O-serotypes of invasive Escherichia coli disease in patients admitted to tertiary care hospitals. |
|---|---|
| Authors: | Geurtsen J; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., Doua J; Janssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica, Beerse, Belgium at the time of analysis., Martinez-Martinez L; Microbiology Unit, University Hospital Reina Sofia, Córdoba, Spain.; Department of Agricultural Chemistry, Soil Science and Microbiology, University of Cordoba, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain., Ibarra de Palacios P; Clinical Development, Janssen Research & Development, Bern, Switzerland at the time of analysis., Powis J; Department of Medicine, University of Toronto, Toronto, ON, Canada.; Department of Infection Prevention and Control, Michael Garron Hospital, Toronto, ON, Canada., Sims M; Department Internal Medicine, Section of Infectious Diseases and International Medicine, Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA.; Departments of Internal Medicine & Foundational Medical Studies, Oakland University William Beaumont School of Medicine, Rochester, MI, USA., Hermans P; Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands.; European Clinical Research Alliance on Infectious Diseases, Utrecht, The Netherlands., Barraud O; Department of Bacteriology, https://ror.org/01tc2d264CHU Limoges, Limoges, France., Lanotte P; Department of Bacteriology and Department of Microbiology, Bretonneau Hospital Tours University, University of Tours-INRAE, Tours, France., Thaden J; Department of Medicine, https://ror.org/00py81415Duke University School of Medicine, Durham, NC, USA., Go O; Janssen Research & Development, Raritan, NJ, USA., Spiessens B; Janssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica, Beerse, Belgium at the time of analysis., Abbanat D; Janssen Research & Development, Raritan, NJ, USA at the time of analysis., Wagenlehner F; Department of Urology, Pediatric Urology and Andrology, Justus-Liebig University, Giessen, Germany., Matsumoto T; Department of Infectious Diseases, International University of Health and Welfare, Chiba, Japan., Bonten M; Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands.; European Clinical Research Alliance on Infectious Diseases, Utrecht, The Netherlands., Sarnecki M; Clinical Development, Janssen Vaccines, Bern, Switzerland at the time of analysis., Poolman J; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands. |
| Corporate Authors: | BAC0006 Study Group as instructed by the Study Steering Committee |
| Source: | Epidemiology and infection [Epidemiol Infect] 2025 Sep 03; Vol. 153, pp. e109. Date of Electronic Publication: 2025 Sep 03. |
| Publication Type: | Journal Article; Observational Study |
| Journal Info: | Publisher: Cambridge University Press Country of Publication: England NLM ID: 8703737 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-4409 (Electronic) Linking ISSN: 09502688 NLM ISO Abbreviation: Epidemiol Infect Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1469-4409 |
|---|---|
| DOI: | 10.1017/S0950268825100344 |
